Takeda Pharm Stock Price, News & Analysis

Takeda Pharmaceutical presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation the results from the Phase 3 SOLSTICE trial of TAK-620 (maribavir). The study demonstrated a significant increase in CMV viremia clearance among transplant recipients with resistant infections, achieving 62.8% with maribavir against 20.3% with conventional therapies. Maribavir also exhibited lower rates of treatment-related toxicities compared to traditional antiviral options, highlighting its potential as a transformative treatment for CMV infections in transplant patients.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has partnered with IDT Biologika to temporarily use its manufacturing capacity for the COVID-19 vaccine developed by Janssen Pharmaceuticals. This arrangement allows Takeda to support global vaccination efforts while ensuring that its dengue vaccine candidate, TAK-003, can resume production shortly after. The company remains dedicated to addressing both COVID-19 and dengue, acknowledging the significant public health needs associated with these diseases.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has submitted a New Drug Application (NDA) for lanadelumab, a monoclonal antibody therapy, to the MHLW in Japan. This treatment targets hereditary angioedema (HAE), a rare genetic disorder affecting 2,000-3,000 people in Japan, of whom only 450 are diagnosed. Lanadelumab proved effective in reducing monthly HAE attacks by up to 87% in clinical trials. If approved, it will be available as a pre-filled syringe, enhancing treatment access for patients with unmet medical needs.

Takeda Pharmaceutical Company Limited (TAK) aims for over JPY 1 trillion (approx. US$9 billion) in revenue from its Growth and Emerging Markets Business Unit by FY2030, signaling more than double its current revenues. This growth strategy focuses on key markets like Brazil, China, and India, with over 20% expected annual growth in China. Takeda plans to enhance access to innovative therapies, including a dengue vaccine candidate (TAK-003), to address unmet patient needs. The company emphasizes a patient-centric approach while maintaining a commitment to local health systems.

BioLife Plasma Services, a division of Takeda, announced the opening of a new plasma donation center in Deptford, New Jersey, to address the rising demand for plasma donations, particularly due to the pandemic. This center will generate approximately $2-3 million annually through donor compensation and create 60 jobs in the community. The facility is part of a network of over 140 centers, known for their high safety standards, and aims to provide essential therapies for patients with rare conditions. The center opens on March 13, and strict health measures are in place to ensure donor safety.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced its decision to acquire Maverick Therapeutics, Inc., specializing in bispecific T-cell targeted immunotherapies. This acquisition includes Maverick's COBRA™ platform and key candidates like TAK-186 and TAK-280, aimed at treating specific solid tumors. The transaction, valued up to $525 million, hinges on antitrust reviews and is anticipated to finalize in Q1 of Takeda's fiscal year 2021. This strategic move enhances Takeda's oncology portfolio and development capabilities, strengthening its commitment to innovative cancer treatments.

Takeda Pharmaceutical Company and Ovid Therapeutics announced an exclusive agreement for Takeda to gain global rights to develop and commercialize soticlestat for treating developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome. Takeda will pay Ovid $196 million upfront and could pay up to $660 million in milestones. This agreement relieves Ovid from further financial obligations related to the original collaboration. Phase 3 studies are set to begin in Q2 2021, building on positive Phase 2 ELEKTRA study results.

Children's National Hospital and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) have launched the Rare Disease Clinical Activity Protocols (Rare-CAP) program. This initiative aims to standardize diagnosis and care for patients with rare diseases, supported by a $3.85 million investment from Takeda over five years. Rare-CAP will utilize a protocol platform that engages patients and families, providing real-time updates. The partnership emphasizes Takeda's commitment to innovation in rare diseases, as these conditions often lack standardized care protocols.

Takeda Pharmaceutical has agreed to transfer marketing rights and assets of four non-core type 2 diabetes products to Teijin Pharma for JPY 133 billion. This divestment, which generated JPY 30.8 billion in sales in FY2019, aligns with Takeda's strategy to focus on core areas such as Gastroenterology and Oncology. Proceeds from the sale will be used to reduce debt, aiming for a net debt/adjusted EBITDA ratio of 2x by FY2023. The transaction is scheduled for completion on April 1, 2021, and is expected to enhance net profit by approximately JPY 90 billion.